NOVEL B0AT1 INHIBITOR
개요
출원인
MITSUBISHI TANABE PHARMA CORPORATION
발명자
Takuya IMAZU; Kazuki NAKAYAMA; Kazunari SHIMOOKA
IPC 분류
CPC 분류
The present invention relates to a compound having a BOAT1 inhibitory action and represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof. In addition, the present invention relates to a BOAT1 inhibitor containing the aforementioned compound and a pharmaceutical composition containing the aforementioned compound. One embodiment of the present invention is, for example, a medicament preferable for the prophylaxis and/or treatment of amino acid metabolism disorders such as phenylketonuria, urea cycle disorder, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, isovaleric acidemia and the like.
원문 (중국어)
The present invention relates to a compound having a BOAT1 inhibitory action and represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof. In addition, the present invention relates to a BOAT1 inhibitor containing the aforementioned compound and a pharmaceutical composition containing the aforementioned compound. One embodiment of the present invention is, for example, a medicament preferable for the prophylaxis and/or treatment of amino acid metabolism disorders such as phenylketonuria, urea cycle disorder, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, isovaleric acidemia and the like.